書籍詳細

第1章 全体像を把握する

P.28 掲載の参考文献

• 1) Alberts B, et al:細胞の分子生物学(原著第3版). 中村桂子ら監訳. 東京:ニュートンプレス;1995.

• 2) 中山敬一編:細胞周期がわかる. 東京:羊土社;2001.

• 3) White M J D:The Chromosomes. 6th ed. London:Chapman and Hall;1973.

• 4) Crow JW:クロー遺伝学概説(原著第8版). 木村資生ら訳. 東京:培風館;1991.

• 5) 奈良信雄ら:臨床検査学講座 遺伝子・染色体検査学. 東京:医歯薬出版;2002.

P.34 掲載の参考文献

• 1) Branden C, et al:タンパク質の構造入門. 勝部幸輝ら監. 東京:教育社;1992.

• 2) Alberts B, et al:Essential細胞生物学. 中村桂子ら監訳. 東京:南江堂;1999.

• 3) 美宅成樹:子どもにきちんと答えられる遺伝子Q&A 100(ブルーバックス). 東京:講談社;2000.

• 4) 美宅成樹:分子生物学入門. 東京:岩波新書;2002.

• 5) 広川貴次, 美宅成樹:できるバイオインフォマティクス. 東京:中山書店;2002.

P.49 掲載の参考文献

• 1) Rodriguez I, et al:A putative pheromone receptor gene expressed in human olfactory mucosa. Nat Genet 2000;26:18-19.

• 2) Nelson G, et al:An amino-acid taste receptor. Nature 2002;416:199-202.
  pubmed

• 3) Lindemann B:Receptors and transduction in taste. Nature 2001;413:219-225.
  pubmed

• 4) Tavernarakis N, et al:Molecular modeling of mechanotransduction in the nematode Caenorhabditis Elegans. Annu Rev Physiol 1997;59:659-689.
  pubmed

• 5) Garcia-Anoveros J, et al:The molecules of mechanosensation. Annu Rev Neurosci 1997;20:567-594.
  pubmed

• 6) Price MP, et al:The mammalian sodium channel BNC1 is required for normal touch sensation. Nature 2000;407:1007-1011.
  pubmed

• 7) North RA:Molecular physiology of P2X receptors. Physiol Rev 2002;82:1013-1067.
  pubmed

• 8) McKemy DD, et al:Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002;416:52-58.
  pubmed

• 9) Xu H, et al:TRPV3 is a calcium-permeable temperature-sensitive cation channel. Nature 2002;418:181-186.
  pubmed

• 10) Smith GD, et al:TRPV3 is a temperature-sensitive vanilloid receptor-like protein. Nature 2002;418:186-190.
  pubmed

• 11) Liedtke W, et al:Vanilloid receptor-related osmotically activated channel(VR-OAC), a candidate vertebrate osmoreceptor. Cell 2000;103:525-535.
  pubmed

• 12) Zhu H, et al:Signal transduction:how do cells sense oxygen? Science 2001;292:449-451.
  pubmed

• 13) Mazza E, et al:Expression of heme oxygenase in the oxygen-sensing regions of the rostral ventrolateral medulla. J Appl Physiol 2001;91:379-385.
  pubmed

• 14) Schuit FC, et al:Glucose sensing in pancreatic β-cells, in gut, pancreas, and hypothalamus. Diabetes 2001;50:1-11.

• 15) Ngarmukos C, et al:Co-localization of GLUT-1 and GLUT4 in the blood-brain barrier of the rat ventromedial hypothalamus. Brain Res 2001;900:1-8.

• 16) Drummond HA, et al:A molecular component of the arterial baroreceptor mechanotransducer. Neuron 1998;21:1435-1442.
  pubmed

• 17) Guler AD, et al:Heat-evoked activation of the ion channel, TRPV4. J Neurosci 2002;22:6408-6414.
  pubmed

• 18) 深田順一;神経・免疫・内分泌相関. 井村裕夫ら編. 科学としての内科学. 最新内科学大系2. 東京:中山書店;1996. pp253-261.

P.57 掲載の参考文献

• 1) 安保徹:絵でわかる免疫. 東京:講談社;2001.

• 2) 菊池浩吉ら編:医科免疫学. 東京:南江堂;2001.

• 3) 多田富雄監訳:免疫学イラストレイテッド. 東京:南江堂;2000.

P.65 掲載の参考文献

• 1) Kirkwood TBL:Evolution of aging. Nature 1977;270:301-304.

• 2) Hayflick L:The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965;37:614-636.
  pubmed

• 3) Harley CB, et al:Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-460.
  pubmed

• 4) Cutler RG:Species probes, longevity and aging. In:Regelson W, et al, editors. Intervention in the Aging Process. Part B:Basic Research and Preclinical Screening. New York:Alan R. Liss, Inc.;1983. p.69-144.

• 5) Brown-Borg HM, et al:Dwarf mice and the aging process. Nature 1996;384:33.
  pubmed

• 6) Holzenberger M, et al:IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003;421:182-187.
  pubmed

• 7) Migliaccio E, et al:The p66SHC adaptor protein controls oxidative stress response and life span in mammals. Nature 1999;402:309-313.
  pubmed

• 8) Roth GS, et al:Biomarkers of caloric restriction may predict longevity in humans. Science 2002;297:811.
  pubmed

• 9) 近藤昊, 井藤英喜著:老化. 東京:山海堂;2001.

• 10) 近藤昊:生物学からみた老化. 井藤英喜編. 看護のための最新医学講座17巻 老人の医療. 東京:中山書店;2001. p.15-18.

P.72 掲載の参考文献

• 1) 藤正巖:見えない機械-細胞の構造とマイクロマシン. テクノライフ選書. 東京:オーム社;1994. p.146.

• 2) 本川達雄:ゾウの時間ネズミの時間-サイズの生物学. 中公新書. 東京:中央公論社;1992. p.230.

• 3) Drexler KE:Engines of Creation-The Coming Era of Nanotechnology. New York:Anchor Press, Doubleday;1986. p.298.

• 4) Gould SJ:Wonderful Life-The Burgess Shale and the Nature of History. New York:WW Norton;1989. p.347.

• 5) レナート・ニルソン:クローズアップネイチャー-ミクロの世界を探る. 長野敬ら訳. 東京:講談社;1985. p.82.

• 6) Goodsell DS:The Machinery of Life. New York:Springer-Verlarg;1992. p.140.

P.78 掲載の参考文献

• 1) 石田直理雄:生物時計のはなし-サーカディアンリズムと時計遺伝子. 東京:羊土社;2000.

• 2) 島田和幸ら:現代医療 2002;34:1-165.

• 3) 御子柴克彦:Bio Science用語ライブラリー1997(実験医学別冊);10:216-217.

• 4) Reppert SM, et al:Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol 2001;63:647-676.
  pubmed

• 5) Ishida N, et al:Circadian rhythm biochemistry:from protein degradation to sleep and mating. Biochem Biophys Res Commun 2001;286:1-5.
  pubmed

• 6) Panda S, et al:Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 2002;109:307-320.
  pubmed

• 7) Miyazaki K, et al:Nuclear entry mechanism of rat PER2(rPER2):role of rPER2 in nuclear localization of CRY protein. Mol Cell Biol 2001;21:6651-6659.
  pubmed

• 8) 山崎紀彦ら:ブレインサイエンス 1997;8:67-76.
  Medical*Online

• 9) Toh KL, et al:An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. Science 2001;291:1040-1043.
  pubmed

• 10) Ebisawa T, et al:EMBO reports 2001;21:342-346.

• 11) 現在投稿準備中

• 12) Iwanaga H, et al:23rd ESPEN 2001;69:282.

第2章 検査から学ぶ分子生物学

P.87 掲載の参考文献

• 1) 肝機能検査法の選択基準. 日本消化器病学会誌 2001;98:200-205.

• 2) 村脇義和ら:肝機能検査. 図説消化器病シリーズ1, 消化器疾患の臨床検査. 東京:メジカルビュー社;2000. p.82-101.

• 3) AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002;123:1367-1384.
  pubmed

• 4) 村脇義和ら:高脂血症を伴う疾病:肝疾患. 臨床と研究 1995;72:1915-1920.
  Medical*Online

• 5) 村脇義和ら:経過観察における肝線維化マーカーの有用性. 肝胆膵 2002;44:633-642.
  Medical*Online

P.95 掲載の参考文献

• 1) 二瓶宏:腎機能検査. 金井泉原著, 金井正光編. 臨床検査法提要 改訂第31版. 東京:金原出版;1998.

• 2) Jalanko H, et al:Genetic kidney diseases disclose the pathogenesis of proteinuria. Ann Med 2001;33:526-533.
  pubmed

• 3) 池田昌弘:機能蛋白と腎疾患:糸球体の透過性制御因子としてのネフリン. 小児科 2002;43:154-162.

• 4) 近藤秀治ら:蛋白尿-そのダイナミックスとストラテジー;Hereditary FSGS. 腎と透析 2002;53:607-611.

• 5) 野々口博史ら:腎生理的機能調節系の分子生物学:バゾプレシン. 腎と透析 1998;45:213-217.

P.118 掲載の参考文献

• 1) 広範囲血液・尿化学検査, 免疫学検査-その数値をどう読むか XII. 腫瘍マーカー. 日本臨牀(増刊号) 1999;57:439-611, 755.

• 2) 腫瘍マーカー. 高久史麿監. 臨床検査データブック1999-2000. 東京:医学書院;1999. p423-448.

• 3) 腫瘍マーカー. Medical Practice編集委員会編. 臨床検査ガイド2001-2002. 東京:文光堂;2001. p.918-967.

• 4) 検査値から読む病態と診断計画VIII-腫瘍マーカー. 臨床医(増刊号) 2002;28:1269-1331.

• 5) 特集 肝胆膵癌の腫瘍マーカー. 肝胆膵 2002;44:717-853.

第3章 身近な疾患から学ぶ分子生物学

P.128 掲載の参考文献

• 1) 大森信彦ほか:脳虚血の分子生物学. 神経進歩 2001;45:351-363.

• 2) 大森信彦:脳梗塞病巣の分子病態. 分子脳血管病 2002;1:85-90.
  Medical*Online

• 3) 久原真ほか:神経疾患の病態に関与するアポトーシスとカスパーゼ. 実験医学 2000;18:1774-1780.
  Medical*Online

• 4) 大森信彦:脳梗塞病巣における生と死のシグナルバランス. 分子脳血管病 2002;1:263-268.
  Medical*Online

• 5) 鶴田文憲ほか:生存シグナルとアポプトーシスシグナルのクロストーク. 実験医学 2000;18:1384-1390.

P.133 掲載の参考文献

• 1) 三好功峰ら編:臨床精神医学講座, S9, アルツハイマー病. 東京:中山書店;2000.

• 2) Selkoe DJ:Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest 2002;110:1375-1381.
  pubmed

• 3) Francis R, et al:Aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell 2002;3:85-97.
  pubmed

P.137 掲載の参考文献

• 1) 水野美邦編:EBMのコンセプトをとりいれたパーキンソン病ハンドブック. 東京:中外医学社;2001.

• 2) Mouradian MM:Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 2002;58:179-185.
  pubmed

• 3) Funayama M,et al:A new locus for Parkinson's disease(PARK8)maps to chromosome 12p11.2-q13.1. Ann Neurol 2002;51:296-301.
  pubmed

• 4) Kitada T, et al:Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.

P.145 掲載の参考文献

• 1) Will RG, et al:A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996;347:921-925.
  pubmed

• 2) Sato T, et al:Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts in Japan, January 1979-May 1996. MMWR 1997;46:1066-1069.

• 3) Doh-Ura K, et al:CJD discrepancy. Nature 1991;353:801-802.
  pubmed

• 4) Kitamoto T, et al:Human prion protein with variantr prion protein. Philos Trans R Soc Lond Biol Sci 1994;343:391-398.

• 5) Parchi P, et al:Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999;46:224-233.

• 6) 佐藤猛. 変異型Creutzfeldt-Jakob病の臨床. 神経内科 2002;57:408-412.

• 7) Huang FP, et al:Migrating intestinal dendritic cells transport PrPSc from the gut. J Gen Virology 2002;83:267-271.

• 8) Hepper FL, et al:Transepithelial prion protein transport by M cells. Nature Med 2001;7:976-978.

• 9) Beekes M, et al:Cerebral targeting indicates vagal spread of infection in hamster fed with scrapie. J Gen Virol 1998;79:601-607.
  pubmed

P.160 掲載の参考文献

• 1) Moskowitz MA, et al:Trigeminovascular connections and mechanisms of vascular headache. In:Rose C, et al, editors. Handbook of Clinical Neurology. 4. Amsterdam:Elsevier;1986. p.107-115.

• 2) Welch KMA, et al:Mitochondria, magnesium and migraine. J Neurol Sci 1995;134:9-14.

• 3) 下村登規夫ら:家族性片麻痺性片頭痛. Clinical Neuroscience 2000;18:294-296.

• 4) Shimomura, T, et al:Point mutation in platelet mitochondrial tRNALeu(UUR)patient with cluster headache. Lancet 1994;344:625.
  pubmed

• 5) Buzzi MG, et al:The antimigraine drug, sumatriptan(GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990;99:202-206.
  pubmed

• 6) Buchwalder, A, et al:Exclusion of 5-HT2A and 5-HT2C receptor genes as candidate genes for migraine. Headache 1996;36:254-258.
  pubmed

• 7) Lesch KP, et al:Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531.
  pubmed

• 8) Murakami F, et al:Anxiety traits associated with a polymorphism in the serotonin transporter gene regulatory region in the Japanese. J Hum Genet 1999;44:15-17.
  pubmed

P.165 掲載の参考文献

• 1) 倉智嘉久ら:イオンチャネルの最前線. 医学のあゆみ 2002;201:945-1232.

• 2) Kullmann DM:The neuronal channelopathies. Brain 2002;125(Pt 6):1177-1195.

• 3) Roll P:Epilepsy and ionic channels. Epileptic Disord 2002;4:165-172.
  pubmed

• 4) Hirose S:Genetic abnormalities underlying familial epilepsy syndromes. Brain Dev 2002;24:211-222.
  pubmed

P.170 掲載の参考文献

• 1) National Institute of Health, National Heart,Lung,and Blood Institute:Global strategy for asthma management and prevention, NHLBI/WHO Workshop Report 1995.

• 2) National Institute of Health, National Heart, Lung,and Blood Institute:Global strategy for asthma management and prevention, NHLBI/WHO Workshop Report 2002.

• 3) Barnes PJ, et al:Mechanisms of Action of Glucocorticoids in asthma. Am J Respir Crit Care Med 1996;154(Suppl):521-527.

• 4) Ponta H, et al:Interference of specific transcription factors. Biochem Bipoys Acta 1992;1129:251-261.

• 5) Taylor IK, et al:Effect of cysteinyl-leukotriene receptor antagonist ICI 204:219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subject. Lancet 1991;237:690.

P.174 掲載の参考文献

• 1) Suga M, et al:Mechanisms accounting for granulomatous responses in hypersensitivity pneumonitis. Sarcoidosis Vasculitis Diffuse Lung Dis 1997;14:131.

• 2) Yamasaki H, et al:Polarized type 1 cytokine profile in bronchoalveolar lavage T cells of patients with hypersensitivity pneumonitis. J Immunol 1999;163:3516.
  pubmed

• 3) Jordan JA, et al:Role of IL-18 in Acute Lung Inflammation. J Immunol 2001;167:7060.

• 4) Denis M, et al:Proinflammatory cytokines in hypersensitivity pneumonitis. Am J Respir Crit Care Med 1995;151:164-169.
  pubmed

• 5) Dai H, et al:Elevated levels of soluble TNF receptors in bronchoalveolar lavage fluid in extrinsic allergic alveolitis. Clin Exp Allergy 1999;29:1209.
  pubmed

• 6) Gudmundsson G, et al:Interferon-gamma is necessary for the expression of hypersensitivity pneumonitis. J Clin Invest 1997;99:2386.
  pubmed

• 7) Gudmundsson G, et al:IL-12 modulates expression of hypersensitivity pneumonitis. J Immunol 1998;15:991-999.

• 8) Gudmundsson G, et al:Interleukin-10 modulates the severity of hypersensitivity pneumonitis in mice. Am J Respir Cell Mol Biol 1998;19:812.

P.178 掲載の参考文献

• 1) 小田鈎一郎:細胞工学入門-細胞増殖を正および負に調節する因子-. 東京:共立出版;2001.

P.185 掲載の参考文献

• 1) 動脈硬化診療・疫学委員会:動脈硬化性疾患診療ガイドライン2002年版. 東京:日本動脈硬化学会;2002. p1.

• 2) http://www.ucl.ac.uk/fh

• 3) Yu W, et al:Molecular genetic analysis of familial hypercholesterolemia:spectrum and regional difference of LDL receptor gene mutations in Japanese population. Atherosclerosis 2002;165:335-342.
  pubmed

• 4) Mabuchi H, et al:Causes of death in patients with familial hypercholesterolemia. Atherosclerosis 1986;61:1-6.
  pubmed

• 5) Mabuchi H, et al:Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989;79:225-232.
  pubmed

• 6) Kajinami K, et al:Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Am J Cardiol 1998;82:113-117.
  pubmed

• 7) Downs JR, et al:Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/Tex-CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.

• 8) Grossman M, et al:Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolemia. Nat Genet 1994;6:335-341.

P.195 掲載の参考文献

• 1) Cargill M, et al:Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999;22:231-238.
  pubmed

• 2) Collins FS, et al:Variations on a theme:cataloging human DNA sequence variation. Science 1997;278:1580-1581.
  pubmed

• 3) Fuster V, et al:Clinical-pathological correlations of coronary disease progression and regression. Circulation. 86(6 Suppl):III1-11, 1992.

• 4) Nakai K, et al:Highly multiplexed genotyping of coronary artery disease-associated SNPs using MALDI-TOF mass spectrometry. Hum Mutat 2002;20:133-138.
  pubmed

• 5) Fan JB, et al. Parallel genotyping of human SNPs using generic high-density oligonucleotide tag arrays. Genome Res 2000;10:853-860.
  pubmed

• 6) Kwiatkowski RW, et al:Clinical, genetic, and pharmacogenetic applications of the Invader assay. Mol Diagn 1999;4:353-364.
  pubmed

P.200 掲載の参考文献

• 1) NIH consensus development panel on Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-67.

P.203 掲載の参考文献

• 1) Correa P:A human model of gastric carcinogenesis. Cancer Res 1988;48:3554-3560.

• 2) IARC:Schistosomes, Liver Flukes and Helicobacter pylori. Monographs on the Evaluation of Carcinogenic Risks to Humans. IARC Sci Publ 1994;61:1-241.

• 3) Uemura N, et al:Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
  pubmed

• 4) Covacci A, et al:Helicobacter pylori virulence and genetic geography. Science 1999;284:1328-1333.
  pubmed

• 5) Asahi M, et al:Helicobacter pylori CagA protein can be tyrosine phosphorylated in gastric epithelial cells. J Exp Med 2000;191:593-602.
  pubmed

• 6) Higashi H, et al:SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science 2002;295:683-686.
  pubmed

• 7) Uemura N, et al:Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastro Clin North Am 2000;29:819-829.

P.207 掲載の参考文献

• 1) Davies DJ, et al:Segmental necrotizing glomerulonephritis with antineutrophil cytoplasmic antibody. Possible abovirus aetiology? Br Med J 1982;285:606.

• 2) Broberger O, et al:Autoantibodies in human ulcerative colitis. J Exp Med 1959;110:657-674.
  pubmed

• 3) Hibi T, et al:In vitro anticolon antibody production by mucosal or peripheral blood lymphocytes from patients with ulcerative colitis. Gut 1990;31:1371-1376.
  pubmed

• 4) Das KM, et al:Autoimmunity to cytoskeletal protein tropomyosin. J Immunol 1993;150:2487-2493.
  pubmed

• 5) Saxon A, et al:A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990;86:202-210.
  pubmed

• 6) Falk RJ, et al:Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. New Eng J Med 1988;318:1651-1657.
  pubmed

• 7) Peen E, et al:Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Gut 1993;34:56-62.
  pubmed

• 8) Arimura Y, et al:Serum myeloperoxidase and serum cytokines in antimyeloperoxidase antibody-associated glomerulonephritis. Clin Nephrol 1993;40:256-264.
  pubmed

• 9) Duerr RH, et al:Neutrophil cytoplasmic antibodies:a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991;100:1385-1391.
  pubmed

• 10) Ishida-Okawara A, et al:Purification and characterization of aseanostatins:actinomycete-derived fatty acid inhibitors to myeloperoxidase release from human polymorphonuclear leukocytes. J Antibiot 1991;44:524-532.
  pubmed

P.212 掲載の参考文献

• 1) Carson DA, et al:Apoptosis and disease. Lancet 1993;341:1251-1254.
  pubmed

• 2) Trahey M, et al:A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 1987;238:542-545.

• 3) 渋谷正史ら編:がん遺伝子・がん抑制遺伝子. 東京:中外医学社;1998.

• 4) Nigro JM, et al:Mutation in the p53 gene occur in diverse human tumor types. Nature 1989;342:705-708.
  pubmed

• 5) Knudson AJ, et al:Mutation and cancer:Statistical study of Retinoblastoma. Proc Nat Acad Sci 1971;68:820-823.

• 6) Vogelstein B, et al:Genomic alteration during colorectal tumor development. N Eng J Med 1998;319:525-532.

• 7) Nishio I, et al:Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665-669.

• 8) Fearson ER, et al:Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990;247:49-56.

• 9) Fujiya M, et al:Reduced Expression of Syndecan-1 Affects Metastatic Potential and Clinical Outcome in Patients with Colorectal Cancer. Jpn J Cancer Res 2001;92:1074-1081.
  pubmed

• 10) Peltomaki P, et al:Genomic mapping of locus predisposing to human colorectal cancer. Science 1993;260:810-812.
  pubmed

P.217 掲載の参考文献

• 1) 小俣政男:肝癌を視野に入れた肝炎の日常診療. 東京:日本メディカルセンター;1995.

• 2) 小尾俊太郎ら:原発性肝癌. 日本内科学会誌1999;122:S240-248.

P.222 掲載の参考文献

• 1) 日本消化器病学会胆石症検討委員会:日本における胆石の新しい分類. 日本消化器病学会誌, 1986;83:309-316.

• 2) 大菅俊明:消化器疾患と胆汁酸. 胆道 1989;3:378-383.
  Medical*Online

• 3) Osuga T, et al:Experimental formation of gallstones in squirrel monkeys. Proc Soc Exp Biol Med 1971;136:722-726.

• 4) Osuga T, et al:The effect of diet on hepatic bile formation and bile acid metabolism in squirrel monkeys with and without cholesterol gallstones. J Lab Clin Med 1976;88:649-661.
  pubmed

• 5) Osuga T, et al:Relationship between bile composition and gallstone formation in squirrel monkeys. Gastroenterology 1972;63:122-133.
  pubmed

• 6) Honda A, et al:Simultaneous assay of activities of two key enzymes in cholesterol metabolism by gas chromatography-mass spectrometry. J Chromatogr 1991;565:53-66.
  pubmed

• 7) 藤井博:核内オーファンレセプターとその機能. 肝胆膵 2000;41:711-723.

• 8) Lu TT, et al:Molecula basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 2000;6:507-516.

• 9) Goodwin B, et al:A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000;6:517-526.

• 10) Holan KR, et al:Nucleation time:a key factor in the pathogenesis of cholesterol gallstone disease. Gastroenterology 1979;72:611.

• 11) Kibe A, et al:Inhibition of cholesterol formation by apolipoproteins in supersaturated model bile. Science 1984;225:514-516.
  pubmed

• 12) Abei M, et al:Identification of human biliary a1-acid glycoprotein as a cholesterol crystallization promoter. Gastroenterology 1994;106:231-238.

• 13) Shoda J, et al:Increased biliary group II phospholipase A2 and altered gallbladder bile in patients with multiple cholesterol stones. Gastroenterology 1997;112:2036-2047.
  pubmed

P.227 掲載の参考文献

• 1) 川茂幸ら:膵癌と糖鎖抗原. 病理と臨床 1995;13:1709-1714.

• 2) Kawa S, et al:Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. Br J Cancer 1991;64:899-902.
  pubmed

• 3) 村上善則:膵癌における遺伝子異常. 胆と膵 1999;20:725-729.
  Medical*Online

• 4) Watanabe H, et al:Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with pancreatic adenocarcinoma. Jpn J Cancer Res1993;84:961-965.

• 5) Furuya N,et al:Long-term follow-up of patients with chronic pancreatitis and K-ras gene mutation detected in pancreatic juice. Gastroenterology 1997;113:593-598.

P.231 掲載の参考文献

• 1) Schena FP:IgA nephropathy. In:Davison AM, et al, editors. Oxford Textbook of Clinical Nephrology, 2nd ed. Oxford:Oxford University Press;1998. p.537-570.

• 2) Glasssock RJ, et al:Primary glomerular diseases. In:Brenner BM, editors. The Kidney, 5th ed. Philadelphia:WB Saunders Co;1996. p.1392-1497.

• 3) Emancipator SN:IgA nephropathy and Henoch-Schonlein Syndrome. In:Jennette JC, et al editors. Heptinstall's Pathology of the Kidney, 5th ed. Philadelphia:Lippincott-Raven Publishers;1998. p.479-539.

• 4) Iida H, et al:Platelet-derived growth factor(PDGF)and PDGF receptor are induced in mesangial proliferative nephritis in the rat. Proc Natl Acad Sci USA 1991;88:6560-6564.
  pubmed

• 5) Johnson RJ, et al:Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 175:1992;1413-1416.
  pubmed

• 6) Okuda S, et al:Elevated expansion of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 1990;86:453-462.

• 7) Yoshioka K, et al:Transforming growth factor β protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 1993;68:154-163.

P.235 掲載の参考文献

• 1) 副島昭典ら:急性腎不全と酸化ストレス. 吉川敏一編. 別冊医学のあゆみ酸化ストレス. 東京:医歯薬出版;2001. p.246-249.

• 2) Baliga, R. et al:Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis;29:465-477.
  pubmed

• 3) 青柳一正:急性腎不全と活性酸素・NO. 急性腎不全のすべて 2000;9:354-355.

• 4) Paller MS,et al:Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest 1984;74:1156-1164.

• 5) Hansson R, et al:Effect of free radical scavengers on renal circulation after ischemia in the rabbit. Clin Sci 1983;65:605-610.
  pubmed

• 6) Aoyagi K, et al:The role of protein kinase C in the increased generation in isolated rat hepatocytes of the hydroxyl radical by puromycin aminonucleoside. Free Radic Res 2000;32:487-496.
  pubmed

• 7) Walker PD, et al:Gentamicin inhanced production of hydrogen peroxide by renal cortical mitochondria. Am J Physiol 1987;253:C495-C499.

• 8) 吉村哲彦編:生体内一酸化窒素実験(NO)プロトコール. 東京:共立出版. 2000.

P.241 掲載の参考文献

• 1) 日本透析医学会統計調査委員会:わが国の慢性透析療法の現況(2001年12月31日現在). 日本透析医学会;2002.

• 2) Mogensen CE, et al:Microalbuminuria, blood pressure and diabetic renal disease:origin and development of ideas. Diabetologia 1999;42:263-285.
  pubmed

• 3) 繁田幸男:平成3年度糖尿病調査研究報告書. 厚生省;1992. p.320-340.

• 4) American Diabetes Association:Diabetic nephropathy. Diabetes Care 2003;26(Suppl):S94-S98.

• 5) Khoshnoodi J, et al:Unraveling the molecular make-up of the glomerular podocyte slit diaphragm. Exp Nephrol 2001;9:355-359.
  pubmed

• 6) Remuzzi G, et al:Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145-1151.
  pubmed

• 7) 荒木信一:遺伝子多型と腎. 糖尿病性腎症. 腎と透析 2002;53:352-356.

P.246 掲載の参考文献

• 1) 鈴木啓悦ら:総テストステロン・遊離テストステロン. 日本臨床増刊 1999;57:279-282.

• 2) 鈴木啓悦ら:性ホルモン結合グログリン(SHBG). 日本臨床増刊 1999;57:292-294.

• 3) 小宮顕ら:DHT. 日本臨床増刊 1999;57:283-287.

• 4) 鈴木啓悦ら:前立腺癌のホルモン依存性. 日本臨床増刊 2002;60:59-64.

• 5) 鈴木啓悦:アンドロゲン受容体の構造と機能. Hormone Frontier in Gynecology 2001;8:127-132.
  Medical*Online

• 6) 鈴木啓悦:前立腺系統的針生検をめぐる諸問題. 癌と化学療法(印刷中)

• 7) Imamoto T, et al:Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 2001;48:573-578.
  pubmed

• 8) 鈴木啓悦ら:抗アンドロゲン剤の使い方. クリニカ 2002;29:38-43.

• 9) 鈴木啓悦ら:前立腺癌の発症進展の分子機構. 現代医療 2000;32:275-280.

• 10) 鈴木啓悦:特集・ホルモン依存性癌と核内レセプター:前立腺癌とホルモン療法. アンドロゲン受容体の関与. Molecular Medicine 2000;37:1124-1129.

P.256 掲載の参考文献

• 1) 葛谷健ら:糖尿病の分類と診断基準に関する委員会報告. 糖尿病 1999;42:385-404.

• 2) Eisenbarth GS:Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986;314:1360-1368.
  pubmed

• 3) Mathis D, et al:β-cell death during progression to diabetes. Nature 2001;414:792-798.

• 4) Notkins AL:Immunologic and genetic factors in type 1 diabetes. J Biol Chem 2002;277:43545-43548.
  pubmed

• 5) Imagawa A, et al:A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group.N Engl J Med 2000;342:301-307.

• 6) Winer S, et al:Autoimmune islet destruction in spontaneous type 1 diabetes is not β-cell exclusive. Nat Med 2003;9:198-205.

• 7) Langin D:Diabetes, insulin secretion, and the pancreatic beta-cell mitochondrion. N Engl J Med 2001;345:1772-1774.
  pubmed

• 8) Winder WW:Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. J Appl Physiol 2001;91:1017-1028.
  pubmed

• 9) Minokoshi Y, et al:Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343.
  pubmed

• 10) Yamauchi T, et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-1295.
  pubmed

P.261 掲載の参考文献

• 1) Ikegami H, et al:Genetics of insulin-dependent diabetes mellitus. Endocr J 1996;43:605-613.
  pubmed

• 2) Cox NJ, et al:Seven regions of the genome show evidence of linkage to type 1 diabetes in a consensus analysis of 767 multiplex families. Am J Hum Genet 2001;69;820-830.

• 3) Nerup J, et al:A genomewide scan for type 1-diabetes susceptibility in Scandinavian families:identification of new loci with evidence of interactions. Am J Hum Genet 2001;69:1301.
  pubmed

• 4) 池上博司ら:1型糖尿病の疾患感受性遺伝子. 日本臨牀 2002;60(増刊号7):377-382.
  Medical*Online

• 5) She JX:Susceptibility to type 1 diabetes:HLA-DQ and DR revisited. Immunol Today 1996;17:323-329.
  pubmed

• 6) Deschamps I, et al:Life table analysis of the risk of type 1 diabetes mellitus in siblings according to islet cell antibodies and HLA markers. Diabetologia 1992;35:951-957.
  pubmed

• 7) Thomson G, et al:Genetic heterogeneity, modes of inheritance, and risk estimates for a joint study of Caucasians with insulin-dependent diabetes mellitus. Am J Hum Genet 1988;43:799-816.
  pubmed

P.273 掲載の参考文献

• 1) 佐藤祐造ら:エネルギー代謝・肥満研究における最近の動向. 臨床スポーツ医学 2001;18:399-406.
  Medical*Online

• 2) 小林正:インスリン抵抗性の分子機構. 最新医学 1998;53:1210-1216.
  Medical*Online

• 3) Sun XJ, et al:Insulin-induced insulin receptor substrate-1 degradation is mediated by the proteasome degradation pathway. Diabetes 1999;48:1359-1364.
  pubmed

• 4) Griffin ME, et al:Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999;48:1270-1274.
  pubmed

• 5) Paz K, et al:A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997;272:29911-29918.

• 6) Steppan CM, et al:The hormone resistin links obesity to diabetes. Nature 2001;409:307-312.
  pubmed

• 7) Spiegelman BM, et al:Adipogenesis and obesity:Rounding out the big picure. Cell 1996;87:377-389.

• 8) Stefan N, et al.:Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51:1884-1888.
  pubmed

• 9) Chen ZP, et al:AMPK signaling in contracting human skeletal muscle:acetyl-CoA carboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab 2000;279:E1202-1206.
  pubmed

• 10) Hayashi T, et al:Exercise regulation of skeletal muscle glucose transport. Adv Exerc Sports Physiol 1999;5:1-8.

• 11) Oshida Y, et al:Long-term mild jogging increases insulin action despite no influence on body mass index or Vo2 max. J Appl Physiol 1989;66:2206-2210.
  pubmed

• 12) Nagasaki M, et al:Exercise training prevens maturation-induced decreases in insulin receptor sbstrate-1 and phosphatidylinositol 3-kinase in rat skeletal muscle. Metabolism 2000;49:954-959.

• 13) Nakai N, et al:Exercise training prevents maturation-induced decreases in insulin sensitivity. J Appl Physiol 1996;80:1963-1967.
  pubmed

• 14) Huppertz C, et al:Uncoupling protein 3(UCP3)stimulates glucose uptake in muscle cells through a phosphoinositide 3-kinase-dependent mechanism. J Biol Chem 2001;276:12520-12529.
  pubmed

• 15) Hotamisligil GS:The role of TNFα and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-625.

• 16) Kelly DE, et al:Fuel selection in human skeletal muscle in insulin resistance:A reexamination. Diabetes 2000:49;677-683.

• 17) Abel ED, et al:Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 2001;409:729-733.
  pubmed

• 18) Shepherd PR, et al:Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J Biol Chem 1993;268:22243-22246.
  pubmed

• 19) Kim H, et al:Fish oil feeding decreases mature sterol regulatory element-binding protein 1(SREBP-1)by down regulation of SREBP-1c mRNA in mouse liver:A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J Biol Chem 1999;274:25892-25898.
  pubmed

• 20) Pan DA, et al:Skeletal muscle membrane lipid composition is related to adiposity and insulin action. J Clin Invest 1995;96:2802-2808.
  pubmed

P.279 掲載の参考文献

• 1) 吉田俊秀:肥満に弱い日本人. 日経サイエンス 2002;32:26-32.

• 2) 松沢佑次ら:新しい肥満の判定と肥満症の診断基準. 肥満研究 2000;6:18-28.

• 3) 河田照雄:脂肪細胞の分化と特異的機能. 最新医学 1997;52:1078-1086.
  Medical*Online

• 4) Walston J, et al:Time of onset of NIDDM and genetic variation in the β3-adrenergic receptor gene. N Engl J Med 1995;333:343-347.

• 5) Yoshida T,et al:Mutation of β3-adrenergic-receptor gene and response to treatment of obesity. Lancet 1995;346:1433-1434.

• 6) Sakane N,et al:β3-adrenergic-receptor polymorphism:Agenetic marker for visceral fat obesity and the insulin resistance syndrome. Diabetologia 1997;40:200-204.

• 7) 吉田俊秀:肥満症の病期と重症度に合致した治療指針. Atherothrombosis 2002;5:17-21.

P.285 掲載の参考文献

• 1) 治療ガイドライン作成委員会編:高尿酸血症・痛風の治療ガイドライン. 東京:日本痛風・核酸代謝学会;2002.

• 2) 谷口敦夫ら:痛風・高尿酸血症の治療. Mebio 2002;19:61-66.

• 3) 科学技術庁資源調査会編:五訂日本食品成分表. 東京:食品成分研究調査会・医師薬出版;2001.

P.302 掲載の参考文献

• 1) 北村聖編:看護のための最新医学講座, 第9巻 血液・造血器疾患. 東京:中山書店;2001.

• 2) 池田康夫ら編:標準血液病学. 東京:医学書院;2000.

• 3) 三輪史朗ら編:血液病学 第2版. 東京:文光堂;1995.

P.312 掲載の参考文献

• 1) 広瀬進:クロマチンと転写因子. 現代医療 2000;32:365-370.

• 2) 北林一生:ヒストンアセチル化の制御と白血病. 分子細胞治療 2000;1:8-17.

• 3) 松村到ら:造血器腫瘍と細胞周期制御遺伝子. 分子細胞治療 2000;1:454-460.

P.316 掲載の参考文献

• 1) 森下剛久ら編:造血幹細胞移植マニュアル第2版改訂新版. 東京:日本医学館;1998.

• 2) 子安重夫編:免疫学がわかる. 東京:羊土社;2000.

P.321 掲載の参考文献

• 1) Borish L, et al:TH1/TH2 lymphocytes:doubt some more. J Allergy Clin Immunol 1997;99:161-164.

• 2) Costa JJ, et al:The cells of the allergic response:mast cells, basophils, and eosinophils. JAMA 1997:278:1815-1822.
  pubmed

• 3) Holt PG, et al:The role of allergy in the development of asthma. Nature 1999;402:B12-B17.
  pubmed

• 4) Janeway CA, et al:Immunobiology. 5th ed. New York:Garland Publishing;2001.

• 5) Kawakami T, et al:Regulation of mast-cell and basophil function and survival by IgE. Nature Rev Immunol 2002;2:773-786.

• 6) Moffatt MF, et al:Genetics of asthma and inflammation:the status. Curr Opin Immunol 1999;11:606-609.
  pubmed

• 7) Oettgen HC, et al:IgE in asthma and atopy:new insights into the regulation of airway inflammation. J Clin Invest 1999;104:985-993.

• 8) Roitt I, et al:Immunology. 6th ed. London:Mosby;2001.

P.325 掲載の参考文献

• 1) Beaven MA, et al:Signal transduction by Fc receptors:the FcεRI case. Immunol Today 1993;14:222-2226.

• 2) Janeway CA, et al:Immunobiology. 5th ed. New York:Garland Publishing;2001.

• 3) Kawakami T, et al:Regulation of mast-cell and basophil function and survival by IgE. Nature Rev Immunol 2002;2:773-786.

• 4) Marquardt DL, et al:Anaphylaxis. In:Middleton E Jr, et al, editors. Allergy, Principles and Practice. St Louis:Mosby;1999. p.1525-1535.

• 5) Roitt I, et al:Immunology. 6th ed. London:Mosby;2001.

P.330 掲載の参考文献

• 1) DeSwarte RD, et al:Drug allergy. In:Allergic Diseases Diagnosis and Management. 5th ed. Philadelphia:Lippincott-Raven;1997. p.317.

• 2) Grabbe S, et al:Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today 1998;19:37-43.

• 3) Janeway CA, et al:Immunobiology. 5th ed. New York:Garland Publishing;2001.

• 4) Roitt I, et al:Immunology. 6th ed. London:Mosby;2001.

P.335 掲載の参考文献

• 1) 三森経世:免疫学的検査の進歩. Medical Practice 1998;15:2031-2034.
  Medical*Online

• 2) 江崎一子:リウマトイド因子は関節炎発症因子となり得るか. リウマチ科 1996:15:440-447.

• 3) 東威:リウマチ因子. 日本臨牀増刊号 1990;48:615-618.

• 4) 中田宗宏ら:リウマトイド因子と糖鎖構造. 診断と治療 1995;83:1173-1177.

• 5) 海老塚岳彦ら:抗ガラクトース欠損IgG抗体糖鎖測定キットの基準範囲, カットオフ値の設定及び臨床的有用性に関する研究. 臨床と研究1997;74:477-482.

P.342 掲載の参考文献

• 1) 三森経世:抗核抗体研究の進歩-自己抗体が認識する核および細胞質蛋白の構造と機能. リウマチ 1992;32:366-378.

• 2) 三森経世:新しい自己抗体とその対応抗原. 井村裕夫ら監. 最新内科学大系プログレス4, 免疫・アレルギー疾患. 東京:中山書店;1997. p.146-157.

• 3) 三森経世:抗核抗体をどう読むか. medicina 1998;35:1697-1699.

• 4) 三森経世:自己抗体と対応抗原解析. 日本臨床 1999;57:316-322.
  Medical*Online

• 5) 三森経世:抗核抗体研究の進歩. 医学のあゆみ 1999;191:934-938.
  Medical*Online

• 6) 三森経世:自己抗体と自己抗原の分子生物学. 組織培養工学 2001;27:172-174.

P.347 掲載の参考文献

• 1) Gottlieb MS, et al:Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men:evidence of a new acquired cellular immuno-deficiency. N Engl J Med 1981;305:1425-1431.

• 2) Matsushita S:Current status and future issues in the treatment of HIV-1 infection. Int J Hematol 2000;72:20-27.
  pubmed

• 3) Kilby JM, et al:The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide(T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults. AIDS Res Hum Retroviruses 2002;18:685-93.
  pubmed

• 4) Strizki JM, et al:SCH-C(SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:12718-12723.
  pubmed

• 5) Fujiwara T:S-1360, a new HIV integrase inhibitor, repeat-dose pharmacokinetics(PK)and safety in healthy volunteers following oral administration. TuPeB4436, XIV International AIDS Conference, Barcerona, Spain 2002. Abst. Vol I p.375

• 6) Little SJ, et al:Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
  pubmed

• 7) Yeni PG et al:Antiretroviral treatment for adult HIV infection in 2002. Updated recomendations of the international AIDS society-USA panel. JAMA 2002;288:222-235.

P.352 掲載の参考文献

• 1) 中山和彦編:抗うつ薬の科学. 基礎と臨床的検証. 東京:星和書店;1995.

• 2) 加藤忠史:うつ病と双極性障害. 加藤進昌編. 看護のための最新医学講座第12巻精神疾患. 東京:中山書店;2002. p.285-303.

• 3) 森信繁:うつ病の病因・病態. 医学のあゆみ 2001;197:457-461.
  Medical*Online

P.358 掲載の参考文献

• 1) Gottesman II:Schizophrenia genesis:the origin of madness. New York:Freeman and Company;1991.

• 2) Williams J, et al:A meta-analysis and transmission disequilibrium study of association between the dopamine D3 receptor gene and schizophrenia. Mol Psychiatry 1998;3:141-149.

• 3) Williams J, et al:Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia(EMASS)Group. Lancet 1996;347:1294-1296.
  pubmed

• 4) Yoshizawa T, et al:Dose-dependent association of apolipoprotein E allele epsilon 4 with late-onset, sporadic Alzheimer's disease. Ann Neurol 1994;36:656-659.
  pubmed

• 5) Jonsson E, et al:Schizophrenia and neurotrophin-3 alleles. Acta Psychiatri Scand 1997;95:414-419.

• 6) Nayfield SG, et al:Ethical and scientific considerations for chemoprevention research in cohorts at genetic risk for breast cancer. J Cell Biochem 1996;25(Suppl):123-130.

P.363 掲載の参考文献

• 1) Theill LE, et al:RANK-L and RANK:T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002;20:795-823.

• 2) Chen W, et al:Review of current progress in the structure and function of Smad proteins. Chin Med J 2002;115:446-450.
  pubmed

• 3) Yamaguchi A, et al:Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr Rev 2000;21:393-411.
  pubmed

• 4) Katagiri T, et al:Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 2002;8:147-159.
  pubmed

• 5) Simonet WS, et al:Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
  pubmed

• 6) Mizuno A, et al:Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610-615.
  pubmed

P.378 掲載の参考文献

• 1) 藤永恵:がん遺伝子-生命科学の本質に迫る. 東京:講談社;1997.

• 2) 金森康展ら:癌抑制遺伝子の不活化とその機構. 産婦人科の実際 2002;51:1353-1359.

• 3) 大谷清:Rb, p53と細胞増殖抑制. 新女性医学大系41巻 婦人科腫瘍の分子・細胞生物学. 東京:中山書店;2001. p.43-53.

• 4) Kato K, et al:Contribution of enhanced transcriptional activation by ER to[12Val]K-Ras mediated NIH3T3 cell transformation. Oncogene 1997;15:3037-3046.

• 5) Zwijsen RM, et al:CDK-independent activation by estrogen receptor by cyclin D1. Cell 1997;88:405-415.
  pubmed

• 6) Kyo S, et al:Estrogen activates telomerase. Cancer Res 1999;59:5917-5921.
  pubmed

P.384 掲載の参考文献

• 1) 「母体血清マーカー検査に関する見解(報告)」厚生科学審議会先端医療技術評価部会・出生前診断に関する専門委員会, 1998年.

• 2) Snijders RJ, et al:UK multicenter project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998;351:343-346.

• 3) 周産期遺伝カウンセリングシステム構築に関する研究, 平成13年度厚生科学研究(子ども家庭総合研究事業)報告書, 629-634, 2002.

第4章 薬の開発と分子生物学

P.397 掲載の参考文献

• 1) Drews J:Drug discovery:a historical perspective. Science 2000;287:1960-1964.
  pubmed

• 1) 松原謙一ら監:ゲノム創薬-創薬のパラダイムシフト. 東京:中山書店;2001.

• 2) 特集:薬物受容体研究の進歩と薬物療法. 薬局 1999;50:13-20, 31-37.

• 3) 高柳一成:医薬品の開発と受容体-ブラック博士の業績について. 現代化学 1989;214:10-14.

• 4) 山崎恒義編:創薬化学. 東京:丸善;2000.

• 5) 中島祥吉:薬を知りたい-創薬プロジェクトの現場から. 東京:丸善;2001.

• 6) 石川智久ら編:創薬サイエンスのすすめ. 東京:共立出版;2002.

P.404 掲載の参考文献

• 1) 堀了平監, 橋田充編:改訂図解夢の薬剤DDS. 東京:じほう;1997.

• 2) 橋田充:ドラッグデリバリーシステム-創薬と治療への新たなる挑戦. 京都:化学同人;1995.

• 3) 中野眞汎ら:ドラッグデリバリーシステム-現状と将来. 東京:南山堂;1986.

• 4) 高橋俊雄ら編:今日のDDS・薬物送達システム. 大阪:医薬ジャーナル社;1999.

• 5) 今井浩三ら:ついに開始されたモノクローナル抗体による治療. Drug Delivery System 2002;17(1):21-57.

• 6) 川合知二監:図解ナノテクノロジーのすべて. 東京:工業調査会;2001.

P.412 掲載の参考文献

• 1) 田中利男:トランスクリプトーム研究の現状と展望. 辻本豪三ら編. ゲノム機能研究プロトコール. 東京:羊土社;2000. p.22-24.

• 2) Lander ES, et al:Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
  pubmed

• 3) Venter JC, et al:The sequence of the human genome. Science 2001;291:1304-1351.

• 4) 田中利男:トランスクリプトーム解析と創薬科学. 医学のあゆみ 2001;196:400-403.
  Medical*Online

• 5) 田中利男:薬理ゲノミクスとファルマインフォマティクス. 石川智久ら編. 創薬サイエンスのすすめ. 東京:共立出版;2002. p.174-185.

• 6) 田中利男:ゲノム創薬SERIES 4:ゲノム創薬とトランスクリプトーム解析. ゲノム医学 2002;2:93-99.

• 7) Evans WE, et al:Pharmacogenomics:Drug disposition, drug targets, and side effects.N Engl J Med 2003;348:538-549.
  pubmed

• 8) Weinshilboum R:Inheritance and drug response. N Engl J Med 2003;348:553-556.

第5章 分子生物学と倫理

P.423 掲載の参考文献

• 1) 遺伝学的検査に関する監視強化. 保健衛生局長官直属委員会勧告(Enhancing the oversight of genetic tests:Recommendations of the Secretary's Advisory Committee on Genetic Testing). (日本語訳は日本人類遺伝学会のホームページ <http://www6.plala.or.jp/jshg/>に掲載されている)

• 2) 遺伝医学関連8学会(日本人類遺伝学会, 日本遺伝カウンセリング学会, 日本遺伝子診療学会, 日本小児遺伝学会, 日本先天異常学会, 日本先天代謝異常学会, 日本産科婦人科学会, 家族性腫瘍研究会):遺伝学的検査に関するガイドライン」(案) (http://www6.plala.or.jp/jshg/)

P.443 掲載の参考文献

• 1) Pennacchio LA, et al:An apolipoprotein influencing triglycerides in humans an mice revealed by comparative sequencing. Science 2001;294:169-173.
  pubmed

• 2) Patil N, et al:Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science 2001;294:1719-1723.
  pubmed

• 3) Olsson ML, et al:Polymorphism and recombination events at the ABO locus:a major challenge for genomic ABO blood grouping strategies. Transfus Med 2001;11:295-313.

• 4) YIP SP:Sequence variation at the human ABO locus. Ann Hum Genet 2002;66:1-27.
  pubmed